Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Modifioidut immuunisolut (autologiset dendriittisolut) ja rokote (Prevnar) suuriannoksisen ulkoisen sädehoidon jälkeen hoidettaessa potilaita, joilla on ei-leikkauskelvoton maksasyöpä

keskiviikko 30. syyskuuta 2026 päivittänyt: Mayo Clinic

Pilottitutkimus dendriittisolujen kasvaimensisäisestä injektiosta suuriannoksisen konformisen ulkoisen säteen sädehoidon jälkeen potilailla, joilla on ei-leikkauskelvoton maksasyöpä

This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in combination with immune checkpoint inhibition (with bevacizumab and atezolizumab or druvalumab) in treating patients liver cancer that cannot be removed by surgery (unresectable) after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab and durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving autologous dendritic cells and Prevnar in combination with immune checkpoint inhibition after radiotherapy may be safe, and tolerable and may stimulate the body's own immune system to fight against the tumor in patients with unresectable liver cancer.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

PRIMARY OBJECTIVE:

I. Evaluation of safety and tolerability of an autologous dendritic cell (DC) vaccine delivered by intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy (EBRT). (Pilot Study) II. Estimate the progression-free survival rate at 2 years post-registration to see if treatment is efficacious compared to historical data in hepatocellular carcinoma (HCC). (Phase II Group 2) II. Estimate the progression-free survival to see if treatment is efficacious compared to historical data in intrahepatic cholangiocarcinoma (iCCA) patients. (Phase II Group 3)

SECONDARY OBJECTIVES:

I. To assess feasibility in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 versus [vs.] 2 vs. 3).

II. To assess overall response rate in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

III. To assess progression free survival in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

IV. To assess clinical benefit rate in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

V. To assess time to response in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

VI. To assess duration of response in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

VII. To assess overall survival in patients with liver cancer treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

RADIOLOGIC STUDY OBJECTIVE:

I. To assess the radiologic response over time of primary liver tumors treated with high-dose conformal EBRT followed by autologous DC vaccine injection by group (Group 1 vs. 2 vs. 3).

CORRELATIVE RESEARCH OBJECTIVES:

I. To monitor patients' immune response after vaccine therapy by group (Group 1 vs. 2 vs. 3).

II. To assess the immune response to pneumococcal 13-valent conjugate vaccine (Prevnar) and similar pneumococcal vaccines by group (Group 1 vs. 2 vs. 3).

OUTLINE:

PILOT STUDY (GROUP I) (CLOSED WITH AMENDMENT 3): Patients with unresectable intrahepatic cholangiocarcinoma (CCA) undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells intratumorally (IT) on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine intramuscularly (IM) on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity.

PHASE II STUDY (GROUP II): Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab intravenously (IV) over 30-60 minutes and bevacizumab IV over 30-90 minutes starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo an esophagogastroduodenoscopy (EGD) at screening and CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

PHASE II STUDY (GROUP III): Patients with iCCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV over 30-60 minutes and durvalumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 2 weeks and then every 3 months for 1 year (beginning at week 36 or 12 weeks after last autologous dendritic cell dose whichever is earlier). Patients are then followed every 3 months until disease progression, and then every 6 months until 5 years after registration.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

85

Vaihe

  • Vaihe 2
  • Vaihe 1

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

    • Minnesota
      • Rochester, Minnesota, Yhdysvallat, 55905
        • Rekrytointi
        • Mayo Clinic in Rochester
        • Ottaa yhteyttä:
        • Päätutkija:
          • Lewis R. Roberts, MD, PhD
        • Päätutkija:
          • Lionel Kankeu Fonkoua, MD

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Age >= 18 years

  • Pilot study (group 1): Histologic confirmation of intrahepatic CCA (Closed as of amendment 3)

  • Phase II study (group 2): Histologic and/or radiologic confirmation of hepatocellular carcinoma (HCC)

  • Phase II study (group 3): Histologic confirmation of intrahepatic cholangiocarcinoma (iCCA)

  • The following tumor characteristics must be met

    • Unresectable disease: HCC (group 2) or intrahepatic CCA (group 3)

    • Measurable or evaluable disease

    • All lesions should be treatable by EBRT while meeting normal tissue constraints

    • Tumor lesions should be accessible using an ultrasound (US)-guided approach for intratumoral DC injection

    • No evidence of extrahepatic tumor (excluding tumor thrombus) by computed tomography (CT) or magnetic resonance imaging (MRI) scan

      • NOTE: Patients who are not candidates for surgical treatment or for ablation with curative intent are allowed
  • Good candidate for standard of care high-dose conformal EBRT in the view of the investigator

  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

  • GROUP 2 HCC ONLY: Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Absolute lymphocyte count (ALC) >= 500/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Absolute monocyte count (AMC) >= 300/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Platelet count >= 50,000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Hemoglobin >= 9.0 g/dL (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Total bilirubin < 1.5 mg/dL (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x upper limit of normal (ULN) (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Creatinine =< 2 mg/dL (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) =< 1.5 x ULN (obtained =< 15 days prior to registration)

  • GROUP 2 HCC ONLY: Absence of proteinuria at screening as demonstrated by one of the following:

    • Urine protein/creatinine (UPC) ratio < 1.0 at screening OR
    • Urine dipstick for proteinuria < 2+ (patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate =<1g of protein in 24 hours to be eligible)
  • GROUP 3 iCCA ONLY: Absolute neutrophil count (ANC) ≥ 1000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Absolute lymphocyte count ≥ 500/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Absolute monocyte count ≥ 300/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Platelet count ≥ 50,000/mm^3 (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Hemoglobin ≥ 9.0 g/dL (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Total bilirubin < 1.5 x ULN (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ≤ 2.5 x ULN (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: Creatinine ≤ 2 mg/dL (obtained =< 15 days prior to registration)

  • GROUP 3 iCCA ONLY: PT/INR/aPTT ≤ 1.5 x ULN (obtained =< 15 days prior to registration)

    • NOTE: If patient is receiving therapeutic anticoagulation, patient must be on a stable anticoagulant regimen
  • Ability to provide written consent

  • Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)

  • Willingness to provide blood and tissue samples for correlative research purposes

Exclusion Criteria:

  • Any of the following because this study involves an investigational agent, the genotoxic, mutagenic and teratogenic effects of which on the developing fetus and newborn are unknown:

    • Pregnant persons
    • Nursing persons
    • Persons of childbearing potential who are unwilling to employ highly effective contraception during heterosexual intercourse while on this study and for 5 months after the last dose of study medication
  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • Immunocompromised patients and patients known to be HIV positive.

    • NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial if they are stable on anti-retroviral therapy, have a CD4+ T cell count ≥ 200/uL, and have an undetectable viral load
  • Uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection requiring systemic treatment or that could impact patient safety
    • Severe infection ≤ 4 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
    • Significant cardiovascular disease (New York Heart Association [NYHA] class II), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia
    • Or, psychiatric illness/social situations (e.g., substance abuse) that would limit compliance with study requirements
  • Receiving any other investigational agent that would be considered a treatment for the primary neoplasm

  • Other active malignancy =< 1 year prior to registration that is considered by the investigator to interfere with the current treatment or measurement of outcomes

  • Major surgery =< 4 weeks prior to enrollment (other than diagnostic surgery or surgical spacer placement in preparation for radiation treatment), or anticipation of need for a major surgical procedure during the study

  • History of hypersensitivity or anaphylactoid reactions to pneumococcal vaccine or any component of the formulation, including diphtheria toxoid

  • Active or history of autoimmune disease or immune deficiency, including but not limited to,myasthenia gravis, myositis, autoimmune hepatitis, Crohn's disease, inflammatory bowel disease, antiphospholipid antibody syndrome, rheumatoid arthritis, Sjogren syndrome, systemic lupus erythematosus, Guillain-Barre syndrome, multiple sclerosis, Wegener granulomatosis, or similar conditions

    • NOTE: Exceptions are allowed for:

      • Patients with hypothyroidism on thyroid replacement therapy

      • Patients with type 1 diabetes mellitus on insulin regimen

      • Patients with eczema, psoriasis lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of the following conditions are met:

        • Rash must cover < 10% of body surface area
        • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
        • There has been no occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids ≤ 12 months prior to registration
  • Requires anticoagulant treatment (INR > 1.5 x ULN) or use of anti-platelet agents that cannot be discontinued for the intratumoral injection procedure

    • NOTE: Heparin for line patency without detectable lab abnormalities in coagulation will be allowed
  • Corticosteroids =< 2 weeks prior to registration, including oral, intravenous (IV), subcutaneous, or inhaled routes of administration

    • NOTE: Patients on chronic corticosteroids for adrenal insufficiency or other reasons may enroll if they receive less than 10 mg/day of prednisone (or equivalent)

    • NOTE: Exception allowed for patients who need prophylactic steroids prior to imaging for contrast allergies

      • Exception: Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study
      • Exception: Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study
  • History of myocardial infarction =< 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

  • Child Pugh class B or C cirrhosis of the liver

  • Previously received immune modulating therapies including but not limited to immune checkpoint inhibitors targeting PD-1 PDL-1 CTLA4, etc.; or prior dendritic cell therapy

  • Prior liver radiation, including radioembolization

  • GROUP 2 ONLY: Barcelona Clinic Liver Cancer (BCLC) stage D disease

  • GROUP 2 ONLY: History of untreated high-risk gastroesophageal varices

  • Active tuberculosis

  • Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to registration

    • NOTE: Exception for patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study
  • Prior allogeneic stem cell or solid organ transplantation

  • Treatment with a live, attenuated vaccine ≤ 4 weeks prior to registration

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei satunnaistettu
  • Inventiomalli: Crossover-tehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Phase II Group 2 (EBRT, dendritic cells, Prevnar, atezo, bev)

Patients with unresectable HCC undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care atezolizumab IV over 30-60 minutes and bevacizumab IV over 30-90 minutes starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo an EGD at screening and CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

Given IV

Muut nimet:
  • Avastin
  • ABP 215
  • Anti-VEGF
  • Anti-VEGF humanisoitu monoklonaalinen vasta-aine
  • Monoklonaalinen anti-VEGF-vasta-aine SIBP04
  • Anti-VEGF rhuMAb
  • Bevasitsumabi awwb
  • Bevasitsumabi Biosimilar ABP 215
  • Bevasitsumabi Biosimilar BEVZ92
  • Bevasitsumabi Biosimilar BI 695502
  • Bevasitsumabi Biosimilar CBT 124
  • Bevasitsumabi Biosimilar CT-P16
  • Bevasitsumabi Biosimilar FKB238
  • Bevasitsumabi Biosimilar GB-222
  • Bevasitsumab Biosimilar HD204
  • Bevasitsumabi Biosimilar HLX04
  • Bevasitsumabi Biosimilar IBI305
  • Bevasitsumab Biosimilar LY01008
  • Bevasitsumab Biosimilar MIL60
  • Bevasitsumab Biosimilar Mvasi
  • Bevasitsumabi Biosimilar MYL-1402O
  • Bevasitsumabi Biosimilar QL 1101
  • Bevasitsumabi Biosimilar RPH-001
  • Bevasitsumabi Biosimilar SCT501
  • Bevasitsumab Biosimilar Zirabev
  • Bevasitsumab-awwb
  • Bevasitsumab-bvzr
  • BP102
  • BP102 Biosimilar
  • HD204
  • Immunoglobuliini G1 (ihmisen ja hiiren monoklonaalinen rhuMab-VEGF-gamma-ketju anti-ihmisen verisuonten endoteelin kasvutekijä), disulfidi ihmisen ja hiiren monoklonaalisella rhuMab-VEGF-kevytketjulla, dimeeri
  • Mvasi
  • MYL-1402O
  • Rekombinantti humanisoitu monoklonaalinen anti-VEGF-vasta-aine
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • QL1101
  • Bevasitsumab Biosimilar QL1101
  • Vegzelma
  • Alymsys
  • Aybintio
  • Onbevzi
  • Avzivi
  • Oyavas

Undergo MRI

Muut nimet:
  • MRI
  • Lääketieteellinen kuvantaminen, magneettiresonanssi / ydinmagneettinen resonanssi
  • HERRA
  • NMRI
  • Ydinmagneettinen resonanssikuvaus
  • Magneettiresonanssikuvaus (MRI)
  • sMRI
  • Rakenne MRI

Undergo biopsy

Muut nimet:
  • Bx
  • Biopsia

Undergo CT or PET/CT

Muut nimet:
  • CT
  • KISSA
  • Kerroskuvaus
  • Aksiaalinen tietokonetomografia
  • tietokonetomografia
  • TIETOKONETOMOGRAFIA
  • tietokoneistettu aksiaalinen tomografia
  • Tietokonetomografia (CT).
  • Diagnostinen CAT -skannaus

Undergo PET/CT

Muut nimet:
  • Lääketieteellinen kuvantaminen, positroniemissiotomografia
  • LEMMIKKI
  • PET-skannaus
  • PT
  • positroniemissiotomografia

Given IV

Muut nimet:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA

Undergo urine and blood sample collection

Muut nimet:
  • Biologinen näytekokoelma
  • Bionäyte kerätty
  • Näytteiden kokoelma

Undergo high-dose EBRT

Muut nimet:
  • EBRT
  • Lopullinen sädehoito
  • Ulkoinen säteen säteily
  • Ulkoinen sädehoito
  • Ulkoinen palkki RT
  • ulkoinen säteily
  • Ulkoinen säteilyhoito
  • ulkoisen säteen säteilyä
  • Säteily, ulkoinen säde
  • Teleradioterapia
  • Etäterapia
  • Etäterapiasäteily
  • Ulkoinen sädehoito (perinteinen)

Undergo apheresis

Muut nimet:
  • Afereesi
  • Aferesed
  • Veren komponenttien poisto
  • Keräys, Afereesi/Leukafereesi
  • Hemafereesi

Given IM

Muut nimet:
  • Edellinen 13
  • PCV 13
  • PCV13 rokote

Given IT

Undergo EGD

Muut nimet:
  • EGD
  • Ylempi endoskopia
Kokeellinen: Pilot study (pheresis, EBRT, dendritic cells, Prevnar)

Patients with unresectable intrahepatic CCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine IM on day 1 of cycles 2-4 only. Treatment repeats every 28 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. (CLOSED WITH AMENDMENT 3)

Undergo high-dose EBRT

Muut nimet:
  • EBRT
  • Lopullinen sädehoito
  • Ulkoinen säteen säteily
  • Ulkoinen sädehoito
  • Ulkoinen palkki RT
  • ulkoinen säteily
  • Ulkoinen säteilyhoito
  • ulkoisen säteen säteilyä
  • Säteily, ulkoinen säde
  • Teleradioterapia
  • Etäterapia
  • Etäterapiasäteily
  • Ulkoinen sädehoito (perinteinen)

Undergo apheresis

Muut nimet:
  • Afereesi
  • Aferesed
  • Veren komponenttien poisto
  • Keräys, Afereesi/Leukafereesi
  • Hemafereesi

Given IM

Muut nimet:
  • Edellinen 13
  • PCV 13
  • PCV13 rokote

Given IT

Kokeellinen: Phase II Group 3 (EBRT, dendritic cells, Prevnar, atezo, tir)

Patients with iCCA undergo apheresis for dendric cell manufacturing and standard of care high-dose EBRT for 5 or 15 fractions over 1-3 weeks (cycle 1). Patients then receive autologous dendritic cells IT on day 1 of cycles 2-8 and pneumococcal 13-valent conjugate vaccine or other pneumococcal vaccine IM on day 1 of cycles 2-4 only. Patients also receive standard of care durvalumab IV starting on day 2 of cycles 2-8. Treatment repeats every 21 days for up to 7 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT, PET/CT and/or MRI, biopsy and urine and blood sample collection throughout the study.

Undergo MRI

Muut nimet:
  • MRI
  • Lääketieteellinen kuvantaminen, magneettiresonanssi / ydinmagneettinen resonanssi
  • HERRA
  • NMRI
  • Ydinmagneettinen resonanssikuvaus
  • Magneettiresonanssikuvaus (MRI)
  • sMRI
  • Rakenne MRI

Undergo biopsy

Muut nimet:
  • Bx
  • Biopsia

Undergo CT or PET/CT

Muut nimet:
  • CT
  • KISSA
  • Kerroskuvaus
  • Aksiaalinen tietokonetomografia
  • tietokonetomografia
  • TIETOKONETOMOGRAFIA
  • tietokoneistettu aksiaalinen tomografia
  • Tietokonetomografia (CT).
  • Diagnostinen CAT -skannaus

Undergo PET/CT

Muut nimet:
  • Lääketieteellinen kuvantaminen, positroniemissiotomografia
  • LEMMIKKI
  • PET-skannaus
  • PT
  • positroniemissiotomografia

Given IV

Muut nimet:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA

Given IV

Muut nimet:
  • Imfinzi
  • MEDI-4736
  • MEDI4736
  • MEDI 4736

Undergo urine and blood sample collection

Muut nimet:
  • Biologinen näytekokoelma
  • Bionäyte kerätty
  • Näytteiden kokoelma

Undergo high-dose EBRT

Muut nimet:
  • EBRT
  • Lopullinen sädehoito
  • Ulkoinen säteen säteily
  • Ulkoinen sädehoito
  • Ulkoinen palkki RT
  • ulkoinen säteily
  • Ulkoinen säteilyhoito
  • ulkoisen säteen säteilyä
  • Säteily, ulkoinen säde
  • Teleradioterapia
  • Etäterapia
  • Etäterapiasäteily
  • Ulkoinen sädehoito (perinteinen)

Undergo apheresis

Muut nimet:
  • Afereesi
  • Aferesed
  • Veren komponenttien poisto
  • Keräys, Afereesi/Leukafereesi
  • Hemafereesi

Given IM

Muut nimet:
  • Edellinen 13
  • PCV 13
  • PCV13 rokote

Given IT

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Incidence of significant toxicity (Pilot study)
Aikaikkuna: Up to completion of cycle 2 (each cycle is 28 days)

A significant toxicity is defined as a dose limiting toxicity that is possibly, probably, or definitely related to dendritic cell (DC) treatment. Toxicities will be assessed using the Cancer Therapy Evaluation Program active version of the Common Terminology Criteria for Adverse Events.

Up to completion of cycle 2 (each cycle is 28 days)
Progression-free survival rate at 2 years (Phase II)
Aikaikkuna: At 2 years

Defined as the time from registration to disease progression or death due to all causes.

At 2 years
PFS (Phase II Group 3)
Aikaikkuna: Up to 5 years

Defined as the time from registration to disease progression or death due to all causes.

Up to 5 years

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Overall response rate
Aikaikkuna: Up to 1 year post treatment

The overall response rate will be estimated by the number of patients with an objective status of complete response (CR) or partial response (PR) divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true overall response rate will be calculated.

Up to 1 year post treatment
Number of patients who received at least one dose of intratumoral DC injection
Aikaikkuna: Up to 1 year post treatment

The feasibility of the regimen will be estimated by the number of patients who received at least one dose of intratumoral DC injection divided by the total number of patients who received apheresis.

Up to 1 year post treatment
Clinical benefit rate
Aikaikkuna: Up to 1 year post treatment

The clinical benefit rate will be estimated by the number of patients with an objective status of stable disease or CR or PR at any time divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true clinical benefit rate will be calculate

Up to 1 year post treatment
Time to response
Aikaikkuna: Up to 1 year post treatment

Time to response is defined for all evaluable patients who have achieved an objective response as the date of initiation of vaccination treatment to the date at which the patient's objective status is first noted to be either a CR or PR. Time to response will be summarized descriptively using Kaplan-Meier methodology.

Up to 1 year post treatment
Duration of response
Aikaikkuna: Up to 1 year post treatment

Duration of response is defined for all evaluable patients who have achieved an objective response as the date at which the patient's objective status is first noted to be either a CR or PR to the earliest date progression is documented. Duration of response will be summarized descriptively using Kaplan-Meier methodology.

Up to 1 year post treatment
Overall survival
Aikaikkuna: Up to 5 years

Defined as the time from registration to death from any cause.

Up to 5 years
Progression-free survival
Aikaikkuna: Up to 5 years

Defined as the time from registration to disease progression or death due to all causes.

Up to 5 years

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in target lesion measurements
Aikaikkuna: Baseline up to 1 year post treatment

All enhancing lesions will be evaluated over time for each patient. The percent change from baseline in target lesion measurements will be assessed over time. Differences in values over time will be summarized descriptively and graphically.

Baseline up to 1 year post treatment
Change in immunologic correlates before and after vaccination treatment
Aikaikkuna: Baseline up to 1 year post treatment

Change in immunologic correlates before and after vaccination treatment will be evaluated and summarized both quantitatively and graphically. Each of the correlative endpoints will be summarized individually, but will also be evaluated in terms of their relationships to one another; i.e., will use Spearman rank correlation coefficient to assess the correlations between baseline levels as well as between changes before and after treatment in these immunologic markers. In addition, these immunologic markers will be correlated with cancer and treatment related outcomes (e.g. response, adverse events). Relationships will also be explored graphically using scatter plots.

Baseline up to 1 year post treatment

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Tutkijat

  • Päätutkija: Lewis R. Roberts, MD, PhD, Mayo Clinic in Rochester
  • Päätutkija: Lionel Kankeu Fonkoua, MD, Mayo Clinic in Rochester

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Hyödyllisiä linkkejä

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Torstai 19. syyskuuta 2019

Ensisijainen valmistuminen (Arvioitu)

Lauantai 31. elokuuta 2030

Opintojen valmistuminen (Arvioitu)

Lauantai 31. elokuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 6. toukokuuta 2019

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 7. toukokuuta 2019

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 8. toukokuuta 2019

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 5. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 30. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • MC1641
  • R01CA274985 (Yhdysvaltain NIH-apuraha/sopimus)
  • 16-009335 (Muu tunniste: Mayo Clinic Institutional Review Board)
  • R01CA294704 (Yhdysvaltain NIH-apuraha/sopimus)

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa